PKI Stock Overview
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$174.88|
|52 Week High||US$203.16|
|52 Week Low||US$119.95|
|1 Month Change||-9.75%|
|3 Month Change||-1.30%|
|1 Year Change||15.12%|
|3 Year Change||102.20%|
|5 Year Change||234.25%|
|Change since IPO||1,927.59%|
Recent News & Updates
With EPS Growth And More, PerkinElmer (NYSE:PKI) Is Interesting
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|PKI||US Life Sciences||US Market|
Return vs Industry: PKI exceeded the US Life Sciences industry which returned 1.8% over the past year.
Return vs Market: PKI exceeded the US Market which returned 4.2% over the past year.
|PKI Average Weekly Movement||4.2%|
|Life Sciences Industry Average Movement||9.1%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: PKI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PKI's weekly volatility (4%) has been stable over the past year.
About the Company
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
PerkinElmer Fundamentals Summary
|PKI fundamental statistics|
Is PKI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PKI income statement (TTM)|
|Cost of Revenue||US$2.10b|
Last Reported Earnings
Oct 03, 2021
Next Earnings Date
Feb 01, 2022
|Earnings per share (EPS)||8.98|
|Net Profit Margin||22.41%|
How did PKI perform over the long term?See historical performance and comparison
0.2%Current Dividend Yield
Is PerkinElmer undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PKI ($174.88) is trading below our estimate of fair value ($196.32)
Significantly Below Fair Value: PKI is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: PKI is good value based on its PE Ratio (19.5x) compared to the US Life Sciences industry average (39.3x).
PE vs Market: PKI is poor value based on its PE Ratio (19.5x) compared to the US market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: PKI's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: PKI's PB Ratio (3.2x) is in line with the US Life Sciences industry average.
How is PerkinElmer forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PKI's earnings are forecast to decline over the next 3 years (-8.2% per year).
Earnings vs Market: PKI's earnings are forecast to decline over the next 3 years (-8.2% per year).
High Growth Earnings: PKI's earnings are forecast to decline over the next 3 years.
Revenue vs Market: PKI's revenue is expected to decline over the next 3 years (-0.4% per year).
High Growth Revenue: PKI's revenue is forecast to decline over the next 3 years (-0.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PKI's Return on Equity is forecast to be low in 3 years time (16.4%).
How has PerkinElmer performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PKI has high quality earnings.
Growing Profit Margin: PKI's current net profit margins (22.4%) are higher than last year (12.7%).
Past Earnings Growth Analysis
Earnings Trend: PKI's earnings have grown significantly by 42.6% per year over the past 5 years.
Accelerating Growth: PKI's earnings growth over the past year (175.9%) exceeds its 5-year average (42.6% per year).
Earnings vs Industry: PKI earnings growth over the past year (175.9%) exceeded the Life Sciences industry 72.2%.
Return on Equity
High ROE: PKI's Return on Equity (16.3%) is considered low.
How is PerkinElmer's financial position?
Financial Position Analysis
Short Term Liabilities: PKI's short term assets ($2.3B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: PKI's short term assets ($2.3B) do not cover its long term liabilities ($6.8B).
Debt to Equity History and Analysis
Debt Level: PKI's net debt to equity ratio (66.3%) is considered high.
Reducing Debt: PKI's debt to equity ratio has increased from 51.2% to 73.3% over the past 5 years.
Debt Coverage: PKI's debt is well covered by operating cash flow (30.5%).
Interest Coverage: PKI's interest payments on its debt are well covered by EBIT (19.5x coverage).
What is PerkinElmer current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PKI's dividend (0.16%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.37%).
High Dividend: PKI's dividend (0.16%) is low compared to the top 25% of dividend payers in the US market (3.6%).
Stability and Growth of Payments
Stable Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: PKI is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: PKI is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PKI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Prahlad Singh (56 yo)
Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of PerkinElmer, Inc. since December 30, 2019. Dr. Singh serves as the Chairman of the Supervisory Board at EUROIMMUN Medizinische Labordiagnos...
CEO Compensation Analysis
Compensation vs Market: Prahlad's total compensation ($USD9.02M) is about average for companies of similar size in the US market ($USD11.47M).
Compensation vs Earnings: Prahlad's compensation has increased by more than 20% in the past year.
Experienced Management: PKI's management team is considered experienced (3.7 years average tenure).
Experienced Board: PKI's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.7%.
PerkinElmer, Inc.'s employee growth, exchange listings and data sources
- Name: PerkinElmer, Inc.
- Ticker: PKI
- Exchange: NYSE
- Founded: 1937
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$22.070b
- Shares outstanding: 126.20m
- Website: https://www.perkinelmer.com
Number of Employees
- PerkinElmer, Inc.
- 940 Winter Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 23:20|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.